ECSP15004585A - Procesos para la preparación de (s)-3-4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y formas farmacéuticamente aceptables de la misma - Google Patents
Procesos para la preparación de (s)-3-4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y formas farmacéuticamente aceptables de la mismaInfo
- Publication number
- ECSP15004585A ECSP15004585A ECIEPI20154585A ECPI201504585A ECSP15004585A EC SP15004585 A ECSP15004585 A EC SP15004585A EC IEPI20154585 A ECIEPI20154585 A EC IEPI20154585A EC PI201504585 A ECPI201504585 A EC PI201504585A EC SP15004585 A ECSP15004585 A EC SP15004585A
- Authority
- EC
- Ecuador
- Prior art keywords
- oxoisoindolin
- morpholinomethyl
- oxy
- benzyl
- processes
- Prior art date
Links
- -1 (4- (MORPHOLINOMETHYL) BENZYL) OXY Chemical class 0.000 title 1
- IXZOHGPZAQLIBH-UHFFFAOYSA-N 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681477P | 2012-08-09 | 2012-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP15004585A true ECSP15004585A (es) | 2015-12-31 |
Family
ID=49035933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI20154585A ECSP15004585A (es) | 2012-08-09 | 2015-02-06 | Procesos para la preparación de (s)-3-4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y formas farmacéuticamente aceptables de la misma |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9309220B2 (enExample) |
| EP (2) | EP3466942B1 (enExample) |
| JP (1) | JP6444866B2 (enExample) |
| KR (1) | KR20150041650A (enExample) |
| CN (1) | CN104718202B (enExample) |
| AU (1) | AU2013299559B2 (enExample) |
| BR (1) | BR112015002183A2 (enExample) |
| CA (2) | CA2879151C (enExample) |
| CR (1) | CR20150051A (enExample) |
| EC (1) | ECSP15004585A (enExample) |
| ES (2) | ES2914876T3 (enExample) |
| HK (1) | HK1211577A1 (enExample) |
| IL (1) | IL236925A0 (enExample) |
| IN (1) | IN2015DN00845A (enExample) |
| MX (2) | MX2015001633A (enExample) |
| PH (1) | PH12015500214A1 (enExample) |
| RU (1) | RU2015108057A (enExample) |
| SG (1) | SG11201500984QA (enExample) |
| WO (1) | WO2014025978A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3202460T1 (sl) | 2010-02-11 | 2019-10-30 | Celgene Corp | Arilmetoksi izoindolin derivati in sestavki, ki jih obsegajo in metode za uporabo le-teh |
| WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| JP6359563B2 (ja) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| MX2020002010A (es) | 2017-08-21 | 2020-07-13 | Celgene Corp | Procesos para la preparacion de 4,5-diamino-5-oxopentanoato de (s)-terc-butilo. |
| US11529339B2 (en) | 2018-10-01 | 2022-12-20 | Celgene Corporation | Combination therapy for the treatment of cancer |
| CN110194760B (zh) * | 2019-05-27 | 2021-08-17 | 浙江农林大学暨阳学院 | 制备3-亚苄基-2-（7’-喹啉）-2,3-二氢-异吲哚-1-酮类化合物的方法 |
| IL293478A (en) * | 2019-12-02 | 2022-08-01 | Celgene Corp | Treatment for cancer |
| CN113896711A (zh) | 2020-07-06 | 2022-01-07 | 北京诺诚健华医药科技有限公司 | 杂环类免疫调节剂 |
| WO2024064646A1 (en) * | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| WO2024212883A1 (zh) * | 2023-04-11 | 2024-10-17 | 上海科胜药物研发有限公司 | 一种芳基甲氧基异吲哚啉衍生物的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| CA2579291C (en) * | 2004-09-03 | 2011-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| SI2380887T1 (sl) * | 2005-06-30 | 2013-12-31 | Celgene Corporation | Postopki priprave spojin 4-amino-2-/2,6-dioksopiperidin-3-il)izoindolin -1,3-diona |
| US8153659B2 (en) | 2007-03-20 | 2012-04-10 | Celgene Corporation | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| SI3202460T1 (sl) | 2010-02-11 | 2019-10-30 | Celgene Corp | Arilmetoksi izoindolin derivati in sestavki, ki jih obsegajo in metode za uporabo le-teh |
| KR20130038232A (ko) | 2010-03-08 | 2013-04-17 | 낫코 파마 리미티드 | 무수 레날리도마이드 ｆｏｒｍ-ｉ |
| JP6185490B2 (ja) | 2012-02-21 | 2017-08-23 | セルジーン コーポレイション | ３−（４−ニトロ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの固体形態 |
-
2013
- 2013-08-08 RU RU2015108057A patent/RU2015108057A/ru unknown
- 2013-08-08 KR KR20157006015A patent/KR20150041650A/ko not_active Abandoned
- 2013-08-08 CN CN201380052461.7A patent/CN104718202B/zh active Active
- 2013-08-08 WO PCT/US2013/054099 patent/WO2014025978A1/en not_active Ceased
- 2013-08-08 US US13/962,764 patent/US9309220B2/en active Active
- 2013-08-08 BR BR112015002183A patent/BR112015002183A2/pt not_active IP Right Cessation
- 2013-08-08 EP EP18206764.5A patent/EP3466942B1/en active Active
- 2013-08-08 IN IN845DEN2015 patent/IN2015DN00845A/en unknown
- 2013-08-08 MX MX2015001633A patent/MX2015001633A/es active IP Right Grant
- 2013-08-08 JP JP2015526698A patent/JP6444866B2/ja active Active
- 2013-08-08 HK HK15112292.3A patent/HK1211577A1/xx unknown
- 2013-08-08 MX MX2018012684A patent/MX385058B/es unknown
- 2013-08-08 EP EP13753229.7A patent/EP2882736B1/en active Active
- 2013-08-08 CA CA2879151A patent/CA2879151C/en active Active
- 2013-08-08 SG SG11201500984QA patent/SG11201500984QA/en unknown
- 2013-08-08 AU AU2013299559A patent/AU2013299559B2/en active Active
- 2013-08-08 CA CA3108974A patent/CA3108974C/en active Active
- 2013-08-08 ES ES18206764T patent/ES2914876T3/es active Active
- 2013-08-08 ES ES13753229T patent/ES2712652T3/es active Active
-
2015
- 2015-01-26 IL IL236925A patent/IL236925A0/en unknown
- 2015-01-30 PH PH12015500214A patent/PH12015500214A1/en unknown
- 2015-02-05 CR CR20150051A patent/CR20150051A/es unknown
- 2015-02-06 EC ECIEPI20154585A patent/ECSP15004585A/es unknown
-
2016
- 2016-03-02 US US15/058,976 patent/US9975872B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2879151A1 (en) | 2014-02-13 |
| SG11201500984QA (en) | 2015-04-29 |
| HK1211577A1 (en) | 2016-05-27 |
| ES2914876T3 (es) | 2022-06-17 |
| EP3466942B1 (en) | 2022-04-20 |
| CR20150051A (es) | 2015-05-11 |
| PH12015500214A1 (en) | 2015-04-27 |
| AU2013299559B2 (en) | 2017-08-17 |
| MX385058B (es) | 2025-03-14 |
| MX2015001633A (es) | 2015-04-08 |
| EP2882736A1 (en) | 2015-06-17 |
| IN2015DN00845A (enExample) | 2015-06-12 |
| AU2013299559A1 (en) | 2015-02-05 |
| EP2882736B1 (en) | 2019-01-09 |
| US20160251333A1 (en) | 2016-09-01 |
| RU2015108057A (ru) | 2016-09-27 |
| BR112015002183A2 (pt) | 2017-07-04 |
| WO2014025978A1 (en) | 2014-02-13 |
| CA2879151C (en) | 2021-03-30 |
| CN104718202A (zh) | 2015-06-17 |
| US9975872B2 (en) | 2018-05-22 |
| KR20150041650A (ko) | 2015-04-16 |
| CN104718202B (zh) | 2018-11-20 |
| US20140046058A1 (en) | 2014-02-13 |
| CA3108974C (en) | 2023-04-04 |
| JP2015524481A (ja) | 2015-08-24 |
| JP6444866B2 (ja) | 2018-12-26 |
| CA3108974A1 (en) | 2014-02-13 |
| US9309220B2 (en) | 2016-04-12 |
| IL236925A0 (en) | 2015-03-31 |
| ES2712652T3 (es) | 2019-05-14 |
| EP3466942A1 (en) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP15004585A (es) | Procesos para la preparación de (s)-3-4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y formas farmacéuticamente aceptables de la misma | |
| CR20150050A (es) | Sales y formas solidas de (s)-3-(4-((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona y composiciones que comprenden y métodos para utilizar las mismas | |
| IL288506B1 (en) | Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione | |
| EA201391318A1 (ru) | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение | |
| IL244494B (en) | Formulations of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-6,2-dione | |
| MX2015015073A (es) | Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona. |